PLASMINOGEN/ANGIOSTATIN CONVERTING ENZYME

纤溶酶原/血管抑制素转换酶

基本信息

  • 批准号:
    2654230
  • 负责人:
  • 金额:
    $ 21.1万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-04-01 至 2001-01-31
  • 项目状态:
    已结题

项目摘要

Angiostatin is a potent inhibitor of metastatic growth of some solid tumors. It is derived by proteolysis of plasminogen, and consists of the kringle 1-4 domain of plasminogen. Although the enzyme that converts plasminogen to angiostatin is expressed by some primary tumors, the identity of this enzyme, and which tumors express the enzyme remain unknown. We have demonstrated that the PC-3 and DU-145 human prostate cancer lines express the enzyme (or enzymes) necessary and sufficient for angiostatin generation, and this is tentatively designated as plasminogen- angiostatin converting enzyme (PACE). Additional data indicate that PACE activity is a serine protease. In preliminary experiments several purification tools have been identified and characterized which will allow for purification of PACE during this project. These include Reactive Red 120-Agarose (Dye-Ligand chromatography), Hi-Q-Sepharose (anion exchange chromatography) and soybean trypsin inhibitor-sepharose (affinity chromatography). The angiostatin generated in vitro by PC-3 cells is bioactive based on inhibition of endothelial cell proliferation and migration. Angiostatin antigen has been demonstrated in the plasma of athymic mice bearing PC-3 tumors. This proposal is to utilize the purification tools identified to complete the purification of the PACE enzyme or enzymes. If the enzyme is novel, the cDNA will be cloned. Monoclonal antibodies to PACE will be generated which will facilitate development of immunoassays and immunohistochemical staining for PACE. The kinetics of the interaction between PACE and plasminogen in vitro, as well as potential antiangiogenic and anti-metastatic effects of PACE administration in vivo will be analyzed.
血管抑制素是一种有效的固体转移生长抑制剂

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GERALD A SOFF其他文献

GERALD A SOFF的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GERALD A SOFF', 18)}}的其他基金

Histone Deacetylase Inhibitors for Cancer Treatment
用于癌症治疗的组蛋白脱乙酰酶抑制剂
  • 批准号:
    6988925
  • 财政年份:
    2005
  • 资助金额:
    $ 21.1万
  • 项目类别:
PLASMINOGEN/ANGIOSTATIN CONVERTING ENZYME
纤溶酶原/血管抑制素转换酶
  • 批准号:
    2010213
  • 财政年份:
    1997
  • 资助金额:
    $ 21.1万
  • 项目类别:
PLASMINOGEN/ANGIOSTATIN CONVERTING ENZYME
纤溶酶原/血管抑制素转换酶
  • 批准号:
    6150226
  • 财政年份:
    1997
  • 资助金额:
    $ 21.1万
  • 项目类别:
PLASMINOGEN/ANGIOSTATIN CONVERTING ENZYME
纤溶酶原/血管抑制素转换酶
  • 批准号:
    2871900
  • 财政年份:
    1997
  • 资助金额:
    $ 21.1万
  • 项目类别:

相似海外基金

The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
  • 批准号:
    21K17258
  • 财政年份:
    2021
  • 资助金额:
    $ 21.1万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
  • 批准号:
    499958-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 21.1万
  • 项目类别:
    Engage Grants Program
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
  • 批准号:
    6623455
  • 财政年份:
    2002
  • 资助金额:
    $ 21.1万
  • 项目类别:
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
  • 批准号:
    6465958
  • 财政年份:
    2002
  • 资助金额:
    $ 21.1万
  • 项目类别:
Novel Nanoparticle Delivery System for Antineoplastics
新型抗肿瘤纳米颗粒输送系统
  • 批准号:
    6483914
  • 财政年份:
    2002
  • 资助金额:
    $ 21.1万
  • 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
  • 批准号:
    6124630
  • 财政年份:
    1998
  • 资助金额:
    $ 21.1万
  • 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
  • 批准号:
    6329037
  • 财政年份:
    1998
  • 资助金额:
    $ 21.1万
  • 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
  • 批准号:
    2747737
  • 财政年份:
    1998
  • 资助金额:
    $ 21.1万
  • 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
  • 批准号:
    3459680
  • 财政年份:
    1990
  • 资助金额:
    $ 21.1万
  • 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
  • 批准号:
    3459678
  • 财政年份:
    1990
  • 资助金额:
    $ 21.1万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了